Late-stage data throws cold water on Celgene's psoriasis pill

Celgene ($CELG) executives highlight a blockbuster future for the oral psoriasis drug apremilast. But on Saturday, investigators rattled the company's die-hard enthusiasts, noting that new Phase III data fell short of an earlier round that had helped whip up high hopes. Nevertheless, Celgene is on its way to filing for an approval later this year, with good odds of winning a green light from the FDA. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.